word,tfidf
bd,0.23128249418610167
al,0.17552325451613518
disease,0.16751486618583572
et,0.16252283375239573
transplantation,0.16193103731297456
cell,0.15634720844011335
treatment,0.14517955069439098
uveitis,0.1437701990886578
haplo,0.13959572182152977
cells,0.13401189294866858
donor,0.1228442352029462
anti,0.1228442352029462
pd,0.11897562506240114
gvhd,0.117260406330085
use,0.11251580798242784
unrelated,0.11167657745722383
hsct,0.10609274858436264
risk,0.10050891971150144
severe,0.10050891971150144
rituximab,0.09951051783782297
efficacy,0.09376317331868986
randomized,0.09376317331868986
vasculitis,0.08934126196577906
reported,0.08934126196577906
survival,0.08375743309291786
tumor,0.08126141687619787
matched,0.08126141687619787
refractory,0.07817360422005667
cd,0.07723023198709948
sct,0.07501053865495189
mismatched,0.07338458414219505
associated,0.07258977534719549
tnf,0.07258977534719549
myelofibrosis,0.07237128570023489
controlled,0.07138537503744069
mud,0.07020930180645407
hla,0.06875966043370589
major,0.06875966043370589
stem,0.06875966043370589
free,0.06875966043370589
identical,0.06875966043370589
mortality,0.06875966043370589
transplant,0.06700594647433429
combination,0.06345366669994727
ptcy,0.06345366669994727
prospective,0.06345366669994727
ric,0.06332487498770553
hypothesis,0.06318837162580866
effective,0.06318837162580866
biologics,0.06290107212188148
higher,0.06250878221245991
outcome,0.0614221176014731
10,0.0614221176014731
immune,0.0614221176014731
acute,0.0614221176014731
cryoglobulinemia,0.0614221176014731
relapse,0.0614221176014731
ks,0.05625790399121392
role,0.05616744144516326
transplanted,0.05616744144516326
regimen,0.05616744144516326
donors,0.05616744144516326
versus,0.05616744144516326
high,0.055838288728611914
post,0.055838288728611914
remission,0.055838288728611914
recently,0.05552195836245387
cases,0.05552195836245387
l1,0.05552195836245387
head,0.054278464275176165
frequent,0.054278464275176165
improved,0.054278464275176165
baff,0.0524175601015679
blindness,0.0524175601015679
antibody,0.050007025769967926
msc,0.050007025769967926
outcomes,0.050007025769967926
aiec,0.050007025769967926
infectious,0.050007025769967926
immunosuppressive,0.049146511264517856
expression,0.049146511264517856
better,0.049146511264517856
comparing,0.049146511264517856
atg,0.047590250024960465
strong,0.047590250024960465
blockade,0.04523205356264681
significantly,0.04523205356264681
rationale,0.04523205356264681
dramatically,0.04523205356264681
morbidity,0.04523205356264681
phase,0.04467063098288953
evidence,0.04467063098288953
safety,0.04467063098288953
50,0.04467063098288953
involvement,0.04467063098288953
approach,0.04375614754872193
manifestations,0.04375614754872193
reduce,0.04375614754872193
allo,0.04212558108387244
talimogene,0.04212558108387244
lower,0.04212558108387244
laherparepvec,0.04212558108387244
shown,0.04212558108387244
recent,0.04212558108387244
saa,0.04193404808125432
depletion,0.04193404808125432
addressing,0.04193404808125432
kroger,0.04193404808125432
tcz,0.04193404808125432
il6,0.04193404808125432
retrospective,0.04193404808125432
antagonists,0.04193404808125432
virus,0.03965854168746705
efficient,0.03965854168746705
monoclonal,0.03965854168746705
agents,0.03965854168746705
atlg,0.03965854168746705
hematopoietic,0.03908680211002834
posterior,0.03908680211002834
treatments,0.03908680211002834
year,0.03908680211002834
40,0.03908680211002834
chronic,0.03908680211002834
70,0.03908680211002834
response,0.03908680211002834
graft,0.03750526932747594
viral,0.03750526932747594
cyclophosphamide,0.03750526932747594
therapeutic,0.03750526932747594
inflammation,0.03750526932747594
mds,0.03750526932747594
term,0.03750526932747594
adalimumab,0.03750526932747594
threatening,0.03750526932747594
young,0.036185642850117446
increasing,0.036185642850117446
2019,0.036185642850117446
highly,0.036185642850117446
curative,0.036185642850117446
intestinal,0.036185642850117446
properties,0.036185642850117446
cd38,0.036185642850117446
induced,0.035104650903227036
aml,0.035104650903227036
intermediate,0.035104650903227036
fludarabine,0.035104650903227036
niu,0.035104650903227036
correlated,0.035104650903227036
reduced,0.035104650903227036
repeated,0.035104650903227036
20,0.033502973237167145
ocular,0.033502973237167145
poor,0.033502973237167145
therapy,0.033502973237167145
met,0.033502973237167145
systemic,0.033502973237167145
conditioning,0.033502973237167145
activity,0.033502973237167145
increased,0.033502973237167145
group,0.033502973237167145
best,0.033502973237167145
overall,0.033502973237167145
host,0.031726833349973636
question,0.031726833349973636
prevent,0.031726833349973636
despite,0.031726833349973636
dependency,0.031726833349973636
approved,0.031726833349973636
immunosuppressants,0.031726833349973636
resistant,0.031726833349973636
induction,0.031726833349973636
strategy,0.031726833349973636
sight,0.031726833349973636
blys,0.03145053606094074
grafts,0.03145053606094074
presenting,0.03145053606094074
mice,0.03145053606094074
deletion,0.03145053606094074
effector,0.03145053606094074
cbt,0.03145053606094074
iusg,0.03145053606094074
firm,0.03145053606094074
fda,0.03145053606094074
ist,0.03145053606094074
increases,0.03145053606094074
elt,0.03145053606094074
significant,0.031254391106229955
effects,0.031254391106229955
incidence,0.031254391106229955
able,0.031254391106229955
treosulfan,0.02808372072258163
abo,0.02808372072258163
age,0.02808372072258163
currently,0.02808372072258163
demonstrate,0.02808372072258163
mycophenolate,0.02808372072258163
directly,0.02808372072258163
mismatch,0.02808372072258163
mofetil,0.02808372072258163
setting,0.02808372072258163
sibling,0.02808372072258163
evaluate,0.02808372072258163
main,0.027919144364305957
second,0.027919144364305957
ii,0.027919144364305957
steroids,0.027919144364305957
60,0.027919144364305957
management,0.027919144364305957
early,0.027919144364305957
capmatinib,0.027919144364305957
benefit,0.027919144364305957
data,0.027919144364305957
level,0.027919144364305957
observed,0.027919144364305957
2009,0.027139232137588083
cord,0.027139232137588083
tumors,0.027139232137588083
csf,0.027139232137588083
pd1,0.027139232137588083
metabolism,0.027139232137588083
inhibitors,0.027139232137588083
leading,0.027139232137588083
achieve,0.027139232137588083
replication,0.027139232137588083
biologic,0.027139232137588083
suggest,0.027139232137588083
propose,0.027139232137588083
demonstrated,0.027139232137588083
type,0.025003512884983963
red,0.025003512884983963
cancer,0.025003512884983963
iii,0.025003512884983963
vascular,0.025003512884983963
terms,0.025003512884983963
neurological,0.025003512884983963
antibiotic,0.025003512884983963
allogeneic,0.025003512884983963
anemia,0.025003512884983963
population,0.025003512884983963
2014,0.025003512884983963
antibodies,0.025003512884983963
ssc,0.025003512884983963
line,0.025003512884983963
international,0.025003512884983963
reduction,0.025003512884983963
serum,0.025003512884983963
good,0.025003512884983963
infusion,0.025003512884983963
inflammatory,0.025003512884983963
effect,0.025003512884983963
compared,0.025003512884983963
long,0.025003512884983963
experimental,0.025003512884983963
updated,0.023795125012480232
carcinoma,0.023795125012480232
haploidentical,0.023795125012480232
important,0.023795125012480232
option,0.023795125012480232
2015,0.023795125012480232
superior,0.023795125012480232
alternative,0.023795125012480232
mainly,0.023795125012480232
efs,0.023795125012480232
targeting,0.023795125012480232
derived,0.023795125012480232
acquired,0.023795125012480232
inhibition,0.023795125012480232
rejection,0.023795125012480232
registry,0.023795125012480232
european,0.023795125012480232
adults,0.023795125012480232
checkpoint,0.023795125012480232
leukemia,0.023795125012480232
45,0.023795125012480232
antidepressant,0.023795125012480232
antigen,0.023795125012480232
treated,0.022335315491444765
grade,0.022335315491444765
behcets,0.022335315491444765
infections,0.022335315491444765
increase,0.022335315491444765
life,0.022335315491444765
rate,0.022335315491444765
active,0.022335315491444765
complete,0.022335315491444765
primary,0.022335315491444765
optimal,0.022335315491444765
days,0.022335315491444765
12,0.022335315491444765
phenotypic,0.02106279054193622
depression,0.02106279054193622
potentially,0.02106279054193622
possible,0.02106279054193622
allowing,0.02106279054193622
os,0.02106279054193622
recipient,0.02106279054193622
disorders,0.02106279054193622
especially,0.02106279054193622
grfs,0.02106279054193622
responsible,0.02106279054193622
aa,0.02106279054193622
concentration,0.02106279054193622
rapidly,0.02106279054193622
ref,0.02106279054193622
infliximab,0.02106279054193622
improvement,0.02106279054193622
allele,0.02096702404062716
literature,0.02096702404062716
encouraging,0.02096702404062716
mcc,0.02096702404062716
little,0.02096702404062716
mucocutaneous,0.02096702404062716
supports,0.02096702404062716
raising,0.02096702404062716
novel,0.02096702404062716
hypothesize,0.02096702404062716
designed,0.02096702404062716
developing,0.02096702404062716
hepatocellular,0.02096702404062716
jak,0.02096702404062716
transfusional,0.02096702404062716
unknown,0.02096702404062716
immunity,0.02096702404062716
robin,0.02096702404062716
favorable,0.02096702404062716
gm,0.02096702404062716
remain,0.02096702404062716
guarantees,0.02096702404062716
biotherapies,0.02096702404062716
retina,0.02096702404062716
bregante,0.02096702404062716
ruxolitinib,0.02096702404062716
axis,0.02096702404062716
focus,0.02096702404062716
yielded,0.02096702404062716
presentation,0.02096702404062716
pathway,0.02096702404062716
isohemagglutinins,0.02096702404062716
advocated,0.02096702404062716
raj,0.02096702404062716
compounds,0.02096702404062716
innovative,0.02096702404062716
ada,0.02096702404062716
panuveitis,0.02096702404062716
proinflammatory,0.02096702404062716
sustainable,0.02096702404062716
considering,0.01875263466373797
need,0.01875263466373797
costs,0.01875263466373797
pembrolizumab,0.01875263466373797
2016,0.01875263466373797
received,0.01875263466373797
sparing,0.01875263466373797
classification,0.01875263466373797
transfusions,0.01875263466373797
belimumab,0.01875263466373797
adult,0.01875263466373797
body,0.01875263466373797
nature,0.018092821425058723
intraocular,0.018092821425058723
flu,0.018092821425058723
failed,0.018092821425058723
prognosis,0.018092821425058723
coli,0.018092821425058723
league,0.018092821425058723
tomosynthesis,0.018092821425058723
eular,0.018092821425058723
carrying,0.018092821425058723
selective,0.018092821425058723
goal,0.018092821425058723
remains,0.018092821425058723
reducing,0.018092821425058723
2010,0.018092821425058723
rheumatism,0.018092821425058723
umbilical,0.018092821425058723
replete,0.018092821425058723
categories,0.018092821425058723
issues,0.018092821425058723
activated,0.018092821425058723
expert,0.018092821425058723
ci,0.018092821425058723
attacks,0.018092821425058723
failures,0.018092821425058723
confirm,0.018092821425058723
older,0.018092821425058723
needed,0.018092821425058723
sufficient,0.018092821425058723
promising,0.018092821425058723
proposes,0.018092821425058723
provides,0.018092821425058723
published,0.018092821425058723
receptor,0.018092821425058723
ema,0.018092821425058723
majority,0.018092821425058723
allogenic,0.018092821425058723
discussed,0.018092821425058723
marginal,0.018092821425058723
microbiota,0.018092821425058723
prolonged,0.018092821425058723
preventing,0.018092821425058723
venous,0.018092821425058723
hope,0.018092821425058723
vitro,0.018092821425058723
submitted,0.018092821425058723
oesogastric,0.018092821425058723
successfully,0.018092821425058723
oncolytic,0.018092821425058723
alpha,0.018092821425058723
il,0.018092821425058723
zone,0.018092821425058723
healthy,0.018092821425058723
vessels,0.018092821425058723
syndrome,0.016751486618583573
plasma,0.016751486618583573
vessel,0.016751486618583573
retinal,0.016751486618583573
infection,0.016751486618583573
following,0.016751486618583573
information,0.016751486618583573
arm,0.016751486618583573
available,0.016751486618583573
secondary,0.016751486618583573
france,0.016751486618583573
recommendations,0.016751486618583573
model,0.016751486618583573
30,0.016751486618583573
steroid,0.016751486618583573
eye,0.016751486618583573
administration,0.016751486618583573
evolution,0.016751486618583573
rates,0.016751486618583573
prca,0.016751486618583573
value,0.016751486618583573
intensity,0.015863416674986818
interferon,0.015863416674986818
colonized,0.015863416674986818
compare,0.015863416674986818
enzymes,0.015863416674986818
initiated,0.015863416674986818
arterial,0.015863416674986818
cd20,0.015863416674986818
functional,0.015863416674986818
immunosuppressant,0.015863416674986818
2011,0.015863416674986818
gov,0.015863416674986818
improve,0.015863416674986818
immunomodulatory,0.015863416674986818
development,0.015863416674986818
diagnostic,0.015863416674986818
optimized,0.015863416674986818
proven,0.015863416674986818
prevention,0.015863416674986818
prognostic,0.015863416674986818
prescription,0.015863416674986818
psychiatric,0.015863416674986818
identify,0.015863416674986818
hsv,0.015863416674986818
idiopathic,0.015863416674986818
plus,0.015863416674986818
pain,0.015863416674986818
observational,0.015863416674986818
myeloablative,0.015863416674986818
2017,0.015863416674986818
targets,0.015863416674986818
maintain,0.015863416674986818
median,0.015863416674986818
drugs,0.015863416674986818
mammography,0.015863416674986818
malignancies,0.015863416674986818
lymphoma,0.015863416674986818
tissue,0.015863416674986818
bacteria,0.015863416674986818
invasive,0.015863416674986818
controls,0.015863416674986818
lupus,0.014041860361290815
endemic,0.014041860361290815
aims,0.014041860361290815
elderly,0.014041860361290815
aged,0.014041860361290815
2008,0.014041860361290815
65,0.014041860361290815
95,0.014041860361290815
autoimmune,0.014041860361290815
fully,0.014041860361290815
sarcoma,0.014041860361290815
biomarkers,0.014041860361290815
uncontrolled,0.014041860361290815
involving,0.014041860361290815
reconstitution,0.014041860361290815
addition,0.014041860361290815
recommendation,0.014041860361290815
choice,0.014041860361290815
rapid,0.014041860361290815
treat,0.014041860361290815
chemotherapy,0.014041860361290815
diseases,0.014041860361290815
models,0.014041860361290815
profile,0.014041860361290815
prophylaxis,0.014041860361290815
http,0.014041860361290815
usually,0.014041860361290815
www,0.014041860361290815
aplastic,0.014041860361290815
team,0.014041860361290815
ileal,0.012501756442491982
visual,0.012501756442491982
overload,0.012501756442491982
delayed,0.012501756442491982
obtain,0.012501756442491982
different,0.012501756442491982
confirmed,0.012501756442491982
limited,0.012501756442491982
loss,0.012501756442491982
marrow,0.012501756442491982
double,0.012501756442491982
cov2,0.012501756442491982
previous,0.012501756442491982
antibiotics,0.012501756442491982
comparison,0.012501756442491982
usual,0.012501756442491982
historical,0.012501756442491982
kaposi,0.012501756442491982
tolerance,0.012501756442491982
tocilizumab,0.012501756442491982
isatuximab,0.012501756442491982
engraftment,0.012501756442491982
endpoint,0.012501756442491982
family,0.012501756442491982
exposed,0.012501756442491982
spartalizumab,0.012501756442491982
source,0.012501756442491982
size,0.012501756442491982
assess,0.012501756442491982
iron,0.012501756442491982
factors,0.012501756442491982
requiring,0.012501756442491982
infusions,0.012501756442491982
inhibitor,0.012501756442491982
absence,0.012501756442491982
80,0.012501756442491982
2013,0.012501756442491982
2012,0.012501756442491982
11,0.012501756442491982
sars,0.011167657745722382
assessed,0.011167657745722382
failure,0.011167657745722382
pre,0.011167657745722382
levels,0.011167657745722382
severity,0.011167657745722382
death,0.011167657745722382
peripheral,0.011167657745722382
procedure,0.011167657745722382
probability,0.011167657745722382
period,0.011167657745722382
kg,0.011167657745722382
complications,0.011167657745722382
19,0.011167657745722382
weeks,0.011167657745722382
vitreous,0.011167657745722382
events,0.011167657745722382
anterior,0.011167657745722382
potential,0.011167657745722382
ongoing,0.011167657745722382
considered,0.011167657745722382
toxicity,0.011167657745722382
resolution,0.011167657745722382
test,0.011167657745722382
mg,0.011167657745722382
lymphomas,0.01048351202031358
selecting,0.01048351202031358
mononuclear,0.01048351202031358
arising,0.01048351202031358
mucosal,0.01048351202031358
caucasian,0.01048351202031358
devastating,0.01048351202031358
relatively,0.01048351202031358
relapsed,0.01048351202031358
personalized,0.01048351202031358
lytic,0.01048351202031358
secreted,0.01048351202031358
difficult,0.01048351202031358
difficile,0.01048351202031358
display,0.01048351202031358
patriarca,0.01048351202031358
pathogens,0.01048351202031358
pathophysiology,0.01048351202031358
develops,0.01048351202031358
pathogenesis,0.01048351202031358
paoli,0.01048351202031358
cyp,0.01048351202031358
cyclophophamide,0.01048351202031358
cryoglobulinemic,0.01048351202031358
cryoglobulin,0.01048351202031358
crucial,0.01048351202031358
phlebotomies,0.01048351202031358
redness,0.01048351202031358
recognition,0.01048351202031358
antitumor,0.01048351202031358
antiinflammatory,0.01048351202031358
antidepressants,0.01048351202031358
disappointing,0.01048351202031358
merkel,0.01048351202031358
easier,0.01048351202031358
mechanisms,0.01048351202031358
meaningful,0.01048351202031358
sjogrens,0.01048351202031358
simplex,0.01048351202031358
signal,0.01048351202031358
location,0.01048351202031358
limiting,0.01048351202031358
ligands,0.01048351202031358
eta,0.01048351202031358
epitopes,0.01048351202031358
bashey,0.01048351202031358
dysregulated,0.01048351202031358
drb1,0.01048351202031358
dividing,0.01048351202031358
displaying,0.01048351202031358
mediated,0.01048351202031358
nct02795429,0.01048351202031358
nct02213705,0.01048351202031358
nct01795677,0.01048351202031358
blocking,0.01048351202031358
resistance,0.01048351202031358
2124,0.01048351202031358
pro,0.01048351202031358
psychiatry,0.01048351202031358
proved,0.01048351202031358
promoted,0.01048351202031358
proliferative,0.01048351202031358
contrasting,0.01048351202031358
warranted,0.01048351202031358
metabolizing,0.01048351202031358
hodgkins,0.01048351202031358
younger,0.01048351202031358
herpes,0.01048351202031358
haplomudelederly,0.01048351202031358
capability,0.01048351202031358
cytopathogenic,0.01048351202031358
ophthalmic,0.01048351202031358
obvious,0.01048351202031358
calmettes,0.01048351202031358
calcineurin,0.01048351202031358
busulfan,0.01048351202031358
burden,0.01048351202031358
br3,0.01048351202031358
myelodysplastic,0.01048351202031358
vigorous,0.01048351202031358
authors,0.01048351202031358
asthenia,0.01048351202031358
molecules,0.01048351202031358
microenvironment,0.01048351202031358
dqb1,0.01048351202031358
dme,0.01048351202031358
reset,0.01048351202031358
represents,0.01048351202031358
represent,0.01048351202031358
removes,0.01048351202031358
p450,0.01048351202031358
overproduction,0.01048351202031358
origin,0.01048351202031358
defective,0.01048351202031358
needing,0.01048351202031358
decade,0.01048351202031358
cb,0.01048351202031358
series,0.01048351202031358
sequence,0.01048351202031358
senescence,0.01048351202031358
nowadays,0.01048351202031358
nonsteroidal,0.01048351202031358
blaise,0.01048351202031358
rise,0.01048351202031358
autoreactive,0.01048351202031358
rr,0.01048351202031358
rondelli,0.01048351202031358
nineteen,0.01048351202031358
neoplastic,0.01048351202031358
decisive,0.01048351202031358
improvements,0.01048351202031358
impressive,0.01048351202031358
impairing,0.01048351202031358
immunosuppressors,0.01048351202031358
83,0.01048351202031358
affecting,0.01048351202031358
favourably,0.01048351202031358
favour,0.01048351202031358
innate,0.01048351202031358
infiltrating,0.01048351202031358
gender,0.01048351202031358
adherent,0.01048351202031358
tribeca,0.01048351202031358
transporters,0.01048351202031358
play,0.01048351202031358
transplants,0.01048351202031358
transplantations,0.01048351202031358
transient,0.01048351202031358
furthermore,0.01048351202031358
food,0.01048351202031358
interfering,0.01048351202031358
interestingly,0.01048351202031358
intact,0.01048351202031358
compound,0.01048351202031358
compartments,0.01048351202031358
pure,0.01048351202031358
consequently,0.01048351202031358
confirming,0.01048351202031358
concluded,0.01048351202031358
producing,0.01048351202031358
transporter,0.01048351202031358
depends,0.01048351202031358
82,0.01048351202031358
uvb,0.01048351202031358
58,0.01048351202031358
hyperacute,0.01048351202031358
045,0.01048351202031358
urgently,0.01048351202031358
urgent,0.01048351202031358
unresponsive,0.01048351202031358
unpublished,0.01048351202031358
underwent,0.01048351202031358
gvl,0.01048351202031358
gupta,0.01048351202031358
guided,0.01048351202031358
granulocyte,0.01048351202031358
generated,0.01048351202031358
vary,0.01048351202031358
valuable,0.01048351202031358
valid,0.01048351202031358
uveal,0.01048351202031358
workshop,0.01048351202031358
follicular,0.01048351202031358
induces,0.01048351202031358
individualized,0.01048351202031358
globulins,0.01048351202031358
accuracy,0.01048351202031358
accelerate,0.01048351202031358
image,0.01048351202031358
ifx,0.01048351202031358
genova,0.01048351202031358
genes,0.01048351202031358
venlafaxine,0.01048351202031358
applying,0.01048351202031358
enhances,0.01048351202031358
engaged,0.01048351202031358
leukocyte,0.01048351202031358
led,0.01048351202031358
leaving,0.01048351202031358
largely,0.01048351202031358
anymore,0.01048351202031358
lam,0.01048351202031358
laboratories,0.01048351202031358
knowing,0.01048351202031358
kappa,0.01048351202031358
expansion,0.01048351202031358
staining,0.01048351202031358
produced,0.01048351202031358
spectrum,0.01048351202031358
specificities,0.01048351202031358
specie,0.01048351202031358
sources,0.01048351202031358
solution,0.01048351202031358
luznik,0.01048351202031358
checkpoints,0.01048351202031358
corticoids,0.01048351202031358
pnh,0.01048351202031358
plays,0.01048351202031358
2004,0.01048351202031358
plasmablasts,0.01048351202031358
cytochromes,0.01048351202031358
drastically,0.01048351202031358
dramatic,0.01048351202031358
stability,0.01048351202031358
produce,0.01048351202031358
timeframe,0.01048351202031358
affective,0.01048351202031358
survivals,0.01048351202031358
surveillance,0.01048351202031358
suppression,0.01048351202031358
supporting,0.01048351202031358
evasion,0.01048351202031358
europa,0.01048351202031358
etanercept,0.01048351202031358
itac,0.01048351202031358
thoroughly,0.01048351202031358
therapeutically,0.01048351202031358
aim,0.01048351202031358
extensively,0.01048351202031358
changed,0.01048351202031358
exists,0.01048351202031358
stimulating,0.01048351202031358
colony,0.01048351202031358
colchicine,0.01048351202031358
cni,0.01048351202031358
clones,0.01048351202031358
clinicaltrials,0.01048351202031358
prevents,0.01048351202031358
prescribing,0.01048351202031358
preliminary,0.01048351202031358
precipitating,0.01048351202031358
creates,0.01048351202031358
concept,0.01048351202031358
aggressive,0.01048351202031358
susceptibility,0.01048351202031358
exposing,0.01048351202031358
34,0.009046410712529361
unaffected,0.009046410712529361
tumour,0.009046410712529361
haematological,0.009046410712529361
guide,0.009046410712529361
immunodeficiency,0.009046410712529361
various,0.009046410712529361
useful,0.009046410712529361
48h,0.009046410712529361
held,0.009046410712529361
harvest,0.009046410712529361
haplotype,0.009046410712529361
44,0.009046410712529361
cytopenia,0.009046410712529361
open,0.009046410712529361
occlusion,0.009046410712529361
brands,0.009046410712529361
bowel,0.009046410712529361
native,0.009046410712529361
disappearance,0.009046410712529361
depressive,0.009046410712529361
dependent,0.009046410712529361
dependence,0.009046410712529361
noted,0.009046410712529361
noninfectious,0.009046410712529361
benefits,0.009046410712529361
reticulocytes,0.009046410712529361
respect,0.009046410712529361
availability,0.009046410712529361
auto,0.009046410712529361
scheme,0.009046410712529361
neuro,0.009046410712529361
neoplasm,0.009046410712529361
natural,0.009046410712529361
reliability,0.009046410712529361
pancytopenia,0.009046410712529361
digital,0.009046410712529361
mucosa,0.009046410712529361
background,0.009046410712529361
donation,0.009046410712529361
distinct,0.009046410712529361
assessing,0.009046410712529361
showed,0.009046410712529361
cataract,0.009046410712529361
cardio,0.009046410712529361
relapsing,0.009046410712529361
regulation,0.009046410712529361
persistence,0.009046410712529361
periods,0.009046410712529361
performing,0.009046410712529361
medicines,0.009046410712529361
md,0.009046410712529361
masquerade,0.009046410712529361
ebmt,0.009046410712529361
sole,0.009046410712529361
simple,0.009046410712529361
light,0.009046410712529361
escalation,0.009046410712529361
erythematosus,0.009046410712529361
dropping,0.009046410712529361
mab,0.009046410712529361
crohns,0.009046410712529361
pi,0.009046410712529361
physicians,0.009046410712529361
regarding,0.009046410712529361
recruiting,0.009046410712529361
classical,0.009046410712529361
antigens,0.009046410712529361
species,0.009046410712529361
effusion,0.009046410712529361
effectively,0.009046410712529361
lymphoid,0.009046410712529361
correlate,0.009046410712529361
possibly,0.009046410712529361
pleural,0.009046410712529361
reasonable,0.009046410712529361
rarely,0.009046410712529361
commonly,0.009046410712529361
combine,0.009046410712529361
appeared,0.009046410712529361
apparent,0.009046410712529361
episode,0.009046410712529361
entering,0.009046410712529361
ligand,0.009046410712529361
larger,0.009046410712529361
aplasia,0.009046410712529361
involves,0.009046410712529361
investigated,0.009046410712529361
l2,0.009046410712529361
eventually,0.009046410712529361
alteration,0.009046410712529361
suggesting,0.009046410712529361
suggested,0.009046410712529361
subpopulations,0.009046410712529361
clonal,0.009046410712529361
classified,0.009046410712529361
critical,0.009046410712529361
countries,0.009046410712529361
agent,0.009046410712529361
agency,0.009046410712529361
synthetic,0.009046410712529361
eu,0.009046410712529361
alloreactive,0.009046410712529361
aimed,0.009046410712529361
extreme,0.009046410712529361
explore,0.009046410712529361
experts,0.009046410712529361
expect,0.009046410712529361
agreement,0.009046410712529361
concentrations,0.009046410712529361
composed,0.009046410712529361
components,0.009046410712529361
complication,0.009046410712529361
pyelonephritis,0.009046410712529361
concerns,0.009046410712529361
topical,0.009046410712529361
fibrosis,0.009046410712529361
fatal,0.009046410712529361
familial,0.009046410712529361
adhesive,0.009046410712529361
achieving,0.009046410712529361
transfused,0.009046410712529361
ib,0.009046410712529361
glaucoma,0.009046410712529361
gives,0.009046410712529361
immunosuppressives,0.009046410712529361
91,0.009046410712529361
process,0.009046410712529361
primarily,0.009046410712529361
proteasome,0.009046410712529361
proposal,0.009046410712529361
properly,0.009046410712529361
contain,0.009046410712529361
2018,0.009046410712529361
2000,0.009046410712529361
immunotherapy,0.007931708337493409
abnormal,0.007931708337493409
ab,0.007931708337493409
85,0.007931708337493409
61,0.007931708337493409
action,0.007931708337493409
frequently,0.007931708337493409
forms,0.007931708337493409
purpose,0.007931708337493409
independence,0.007931708337493409
glucocorticoids,0.007931708337493409
thymocyte,0.007931708337493409
affect,0.007931708337493409
fluid,0.007931708337493409
infiltration,0.007931708337493409
advanced,0.007931708337493409
adenocarcinoma,0.007931708337493409
targeted,0.007931708337493409
experience,0.007931708337493409
intolerance,0.007931708337493409
intervention,0.007931708337493409
platform,0.007931708337493409
plasmapheresis,0.007931708337493409
reaches,0.007931708337493409
prescribed,0.007931708337493409
sustained,0.007931708337493409
involve,0.007931708337493409
investigating,0.007931708337493409
large,0.007931708337493409
lack,0.007931708337493409
label,0.007931708337493409
ktr,0.007931708337493409
joint,0.007931708337493409
examinations,0.007931708337493409
success,0.007931708337493409
sub,0.007931708337493409
appears,0.007931708337493409
cyclosporine,0.007931708337493409
phrc,0.007931708337493409
recruited,0.007931708337493409
recovery,0.007931708337493409
recipients,0.007931708337493409
ciprofloxacin,0.007931708337493409
legal,0.007931708337493409
lead,0.007931708337493409
apn,0.007931708337493409
eradication,0.007931708337493409
earlier,0.007931708337493409
male,0.007931708337493409
eltrombopag,0.007931708337493409
cd8,0.007931708337493409
relationship,0.007931708337493409
pharmacokinetics,0.007931708337493409
pharmacodynamics,0.007931708337493409
persistent,0.007931708337493409
paper,0.007931708337493409
disorder,0.007931708337493409
marker,0.007931708337493409
easily,0.007931708337493409
social,0.007931708337493409
similar,0.007931708337493409
attenuated,0.007931708337493409
minimal,0.007931708337493409
mild,0.007931708337493409
metastatic,0.007931708337493409
does,0.007931708337493409
arthritis,0.007931708337493409
segment,0.007931708337493409
beneficial,0.007931708337493409
direct,0.007931708337493409
dfs,0.007931708337493409
brochure,0.007931708337493409
panel,0.007931708337493409
murine,0.007931708337493409
mscs,0.007931708337493409
average,0.007931708337493409
schedule,0.007931708337493409
safe,0.007931708337493409
block,0.007931708337493409
myeloid,0.007931708337493409
numbers,0.007931708337493409
blind,0.007931708337493409
bilateral,0.007931708337493409
rifaximin,0.007931708337493409
whichever,0.007931708337493409
undergoing,0.007931708337493409
immunization,0.007931708337493409
hhv8,0.007931708337493409
59,0.007931708337493409
54,0.007931708337493409
49,0.007931708337493409
hepatic,0.007931708337493409
world,0.007931708337493409
human,0.007020930180645407
hypertension,0.007020930180645407
hemolytic,0.007020930180645407
hematological,0.007020930180645407
identified,0.007020930180645407
unacceptable,0.007020930180645407
consumption,0.007020930180645407
hgf,0.007020930180645407
require,0.007020930180645407
observations,0.007020930180645407
described,0.007020930180645407
deterioration,0.007020930180645407
blinded,0.007020930180645407
nomenclature,0.007020930180645407
detailed,0.007020930180645407
bleeding,0.007020930180645407
respond,0.007020930180645407
binding,0.007020930180645407
2003,0.007020930180645407
180,0.007020930180645407
occurring,0.007020930180645407
determine,0.007020930180645407
scores,0.007020930180645407
needs,0.007020930180645407
pan,0.007020930180645407
real,0.007020930180645407
standardization,0.007020930180645407
lymphocytes,0.007020930180645407
allows,0.007020930180645407
kidney,0.007020930180645407
eyes,0.007020930180645407
endoscopic,0.007020930180645407
class,0.007020930180645407
entry,0.007020930180645407
cutaneous,0.007020930180645407
cure,0.007020930180645407
decreased,0.007020930180645407
measured,0.007020930180645407
mesylate,0.007020930180645407
discontinued,0.007020930180645407
particular,0.007020930180645407
regression,0.007020930180645407
relapses,0.007020930180645407
medicine,0.007020930180645407
beginning,0.007020930180645407
attributed,0.007020930180645407
determined,0.007020930180645407
difference,0.007020930180645407
damage,0.007020930180645407
cytokines,0.007020930180645407
cytokine,0.007020930180645407
occurs,0.007020930180645407
thymoglobulin,0.007020930180645407
tolerated,0.007020930180645407
account,0.007020930180645407
act,0.007020930180645407
grafalon,0.007020930180645407
individuals,0.007020930180645407
provide,0.007020930180645407
proposed,0.007020930180645407
consecutive,0.007020930180645407
product,0.007020930180645407
pulmonary,0.007020930180645407
immunogenicity,0.007020930180645407
immunological,0.007020930180645407
gene,0.007020930180645407
genetic,0.007020930180645407
composite,0.007020930180645407
01,0.007020930180645407
adaptive,0.007020930180645407
activation,0.007020930180645407
target,0.007020930180645407
flare,0.007020930180645407
extra,0.007020930180645407
injections,0.007020930180645407
future,0.007020930180645407
practice,0.007020930180645407
pressure,0.007020930180645407
answer,0.007020930180645407
cohorts,0.007020930180645407
center,0.007020930180645407
conventional,0.007020930180645407
institut,0.007020930180645407
functions,0.007020930180645407
single,0.006250878221245991
syndromes,0.006250878221245991
symptoms,0.006250878221245991
taken,0.006250878221245991
concomitant,0.006250878221245991
concerning,0.006250878221245991
course,0.006250878221245991
occurrence,0.006250878221245991
neutrophil,0.006250878221245991
nk,0.006250878221245991
36,0.006250878221245991
camostat,0.006250878221245991
scale,0.006250878221245991
neutrophils,0.006250878221245991
organ,0.006250878221245991
opinion,0.006250878221245991
25,0.006250878221245991
33,0.006250878221245991
proportion,0.006250878221245991
uninjected,0.006250878221245991
heart,0.006250878221245991
hospitalizations,0.006250878221245991
given,0.006250878221245991
55,0.006250878221245991
responses,0.006250878221245991
notably,0.006250878221245991
normal,0.006250878221245991
skin,0.006250878221245991
selection,0.006250878221245991
sites,0.006250878221245991
regulatory,0.006250878221245991
release,0.006250878221245991
counts,0.006250878221245991
completed,0.006250878221245991
covid,0.006250878221245991
refer,0.006250878221245991
place,0.006250878221245991
mixed,0.006250878221245991
onset,0.006250878221245991
therapies,0.006250878221245991
characteristics,0.006250878221245991
corticosteroids,0.006250878221245991
testing,0.006250878221245991
interaction,0.006250878221245991
presented,0.006250878221245991
present,0.006250878221245991
injected,0.006250878221245991
thrombosis,0.006250878221245991
radiation,0.006250878221245991
classic,0.006250878221245991
liver,0.006250878221245991
allow,0.006250878221245991
sun,0.006250878221245991
factor,0.006250878221245991
investigators,0.006250878221245991
sle,0.006250878221245991
cause,0.006250878221245991
decrease,0.006250878221245991
recommended,0.006250878221245991
evaluated,0.006250878221245991
progression,0.005583828872861191
validated,0.005583828872861191
groups,0.005583828872861191
greater,0.005583828872861191
order,0.005583828872861191
multiple,0.005583828872861191
samples,0.005583828872861191
iv,0.005583828872861191
placebo,0.005583828872861191
macular,0.005583828872861191
chimerism,0.005583828872861191
lesions,0.005583828872861191
edema,0.005583828872861191
duration,0.005583828872861191
doses,0.005583828872861191
date,0.005583828872861191
signs,0.005583828872861191
modified,0.005583828872861191
cardiac,0.005583828872861191
decision,0.005583828872861191
sensitivity,0.005583828872861191
amplification,0.005583828872861191
current,0.005583828872861191
step,0.005583828872861191
count,0.005583828872861191
event,0.005583828872861191
interval,0.005583828872861191
corticosteroid,0.005583828872861191
injection,0.005583828872861191
additional,0.005583828872861191
adverse,0.005583828872861191
independent,0.005583828872861191
quality,0.005583828872861191
previously,0.005583828872861191
includes,0.005583828872861191
followed,0.005583828872861191
